Magnetic resonance imaging-guided salvage high-dose-rate brachytherapy for local recurrence after prostatectomy and external beam radiotherapy.

Authors

Patricia Willisch, Beatriz Vázquez-Barreiro, Aldara Candal, Ana Vilchez, Benito Andrade, Saul Lopez-Soliño, Enrique Cespón, Sara Montemuiño, Iñigo Nieto, Manuel Carballo-Quinta, Marisa Vázquez de la Torre, Francisco Salvador Gomez, Antonio Medina López, Victor Muñoz

Published in

Journal of contemporary brachytherapy. Volume 18. Issue 2. Pages 117-123. Epub Jun 03, 2026.

Abstract

To evaluate the safety and efficacy of high-dose-rate (HDR) prostate brachytherapy (BT) in patients with local relapse after initial treatment with radical prostatectomy and salvage external beam radiation therapy (EBRT).
Patients with local recurrence of prostate adenocarcinoma were retrospectively identified at a single-institution between 2015 and 2024. Recurrence was confirmed by imaging (MRI or choline PET) after prostatectomy and EBRT. Patients had no evidence of distant disease. A total HDR-BT dose of 17 Gy to 20 Gy was administered in two fractions.
Seventeen patients received salvage HDR-BT. The median follow-up time was 74 months (range, 6-100). Twelve patients (70.6%) received salvage-intent EBRT after surgery, while five (29.4%) had adjuvant EBRT. Three patients received androgen deprivation therapy (ADT) concurrently with EBRT in a mean ADT duration of 72 months (range, 6-126). The median time to PSA nadir after EBRT was 14 months. The median interval between EBRT and HDR-BT was 4 years (range, 1-14). After a median follow-up of six years from HDR-BT, 9 (52.9%) patients remained free of local recurrence, and 11 (64.7%) were recurrence-free in the treated region. In terms of toxicity, one patient experienced chronic grade 4 genitourinary toxicity requiring cystectomy, but no acute or late gastrointestinal toxicity was observed. At last follow-up, 15 patients (88.2%) were alive.
In this long-term single-institution series, salvage HDR-BT demonstrates durable local control with acceptable toxicity in patients with local recurrence after prostatectomy and EBRT.

PMID:
42488734
Bibliographic data and abstract were imported from PubMed on 23 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.